A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2004
11/18/2004	WO2003093443A3 Alcam and alcam modulators
11/18/2004	WO2003038043A3 Combinations of dr5 antibody and other therapeutic agents
11/18/2004	WO2003037913A3 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/18/2004	WO2002086087A3 Cytokine protein family
11/18/2004	US20040231009 Using variation in sensory organ developmental genes to diagnose and treat nervous system disorders; tissue engineering and gene therapy
11/18/2004	US20040231005 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases
11/18/2004	US20040229945 use in inhibiting angiogenesis in a mammal
11/18/2004	US20040229944 Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone
11/18/2004	US20040229937 diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
11/18/2004	US20040229932 osteoarthritis; little to no intrinsic estrogenicity; antagonizes the effects of 17 beta -estradiol with minimal uterine stimulation; bone loss inhibitor
11/18/2004	US20040229927 Imidazole derivatives for treatment of allergic and hyperproliferative disorders
11/18/2004	US20040229923 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
11/18/2004	US20040229919 As diuretic agent, as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome
11/18/2004	US20040229912 Polymeric delivery formulations of leuprolide with improved efficacy
11/18/2004	US20040229897 Aid in cytokine biosynthesis
11/18/2004	US20040229889 HDAC inhibitor
11/18/2004	US20040229885 Xanthine phosphodiesterase V inhibitors
11/18/2004	US20040229882 dipeptide or tripeptide MC-1R and MC-4R agonists
11/18/2004	US20040229876 Quinoline derivatives and quinazoline derivatives having azolyl group
11/18/2004	US20040229875 Administering compounds such as 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide for therapy of transplant rejection, melanoma, or a cancer selected from colon, breast, lung, kidney, ovary, pancreas, CNS, or cancer of the gastric tract
11/18/2004	US20040229851 2-Propylidene-19-nor-vitamin D compounds
11/18/2004	US20040229845 Modified PSMA ligands and uses related thereto
11/18/2004	US20040229843 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
11/18/2004	US20040229841 Method for treating cancer using camptothecin derivatives and 5-fluorouracil
11/18/2004	US20040229835 Immunostimulatory nucleic acid molecules
11/18/2004	US20040229834 PREFERENTIAL CLASSIFICATON BETWEEN CANCER CELLS; OBTAIN SAMPLE, MONITOR SAMPLE FOR PREFERENTIAL ENZYMATIC ACTIVITY, EVALUATE DIFFERENTIATED CELLS; for of detecting presence or absence or level of a polynucleotide sequence encoding heparanase in a biological sample
11/18/2004	US20040229833 Therapeutic use of cis-element decays in vivo
11/18/2004	US20040229831 Compositions and methods for non-parenteral delivery of oligonucleotides
11/18/2004	US20040229823 For use in therapy of growth metabolic disorders
11/18/2004	US20040229797 Protein that comprises an amino-acid in which one or several amino acids are deleted, substituted or added, and has effects of controlling cell migration and cell death in L-FILIP, S-FILIP, or other amino-acid sequence
11/18/2004	US20040229795 For oncological diseases and diseases accompanying neovascularization, immune complex-mediated and autoimmune diseases, viral infections, fibrotic and granulomatous diseases, allergic diseases, degenerative diseases of the nervous system and arteriosclerosis
11/18/2004	US20040229323 aerobic fermentation of a biologically pure strain of Streptomyces hygroscopicus LL-D45042 until macrocyclic lactone LL-D45042 is formed, recovery, purification
11/18/2004	US20040229301 Tissue factor antibodies and uses thereof
11/18/2004	US20040229277 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040229232 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229212 Recombinant human mannan-binding lectin
11/18/2004	US20040228925 Stimulating anticarcinogenic immune response using injections of high molecular weight autologous urine isolates containing tumor associated antigens
11/18/2004	US20040228911 Vinorelbine compositions and methods of use
11/18/2004	US20040228877 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
11/18/2004	US20040228876 Composition and Method for Treating Cancer Using Herpes Virus
11/18/2004	US20040228868 induces apoptosis in mammalian cancer cells; irinotecan; kits
11/18/2004	US20040228860 Antibodies to a tumor-associated surface antigen for delivery of diagnostic and therapeutic agents
11/18/2004	US20040228859 inhibit binding of IGF-1 and IGF-II to IGF-IR so they act as antitumor by reducing tumor growth and/or prolonging the time of tumor progression; hybridoma cell lines; methods of preparing the compositions
11/18/2004	US20040228857 administration of a human or humanized antibody expressed and glycosylated in a chinese hamster ovaries (CHO) cell expression system to treat T-cell mediated disorders, autoimmune disorders, cancer and infections; vasculitis, arthritis, lupus, psoriasis, multiple sclerosis, graft versus host disease
11/18/2004	US20040228836 cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC)
11/18/2004	DE19882755B4 Ein Fusionsprotein des hEGF und des humanen Angiogenins und ein Verfahren zu dessen Herstellung A fusion protein of hEGF and human angiogenin, and a process for its preparation
11/18/2004	DE10296942T5 Therapeutische Zusammensetzung, welche die Immunitätsreaktion verändert A therapeutic composition, which changes the immunity reaction
11/18/2004	CA2524924A1 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer
11/18/2004	CA2524626A1 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
11/18/2004	CA2524474A1 Methods of hormonal treatment utilizing extended cycle contraceptive regimens
11/18/2004	CA2523870A1 Claudins' underexpression as markers of tumor metastasis
11/18/2004	CA2523720A1 Synthetic gene encoding human carcinoembryonic antigen and uses thereof
11/18/2004	CA2521700A1 Piperidinyl- and piperazinyl-alkylcarbamate derivatives, preparation and therapeutic application thereof
11/18/2004	CA2519930A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
11/18/2004	CA2518076A1 Medicinal compositions for concomitant use as anticancer agent
11/17/2004	EP1477490A1 Pyrrolopyrimidine derivative
11/17/2004	EP1477489A1 Pyrrolopyrimidine derivatives
11/17/2004	EP1477486A2 Imides as inhibitors of TNF alpha
11/17/2004	EP1477483A1 Vitamin d3 derivatives and remedies using the same
11/17/2004	EP1477482A1 Novel phenylalanine derivative
11/17/2004	EP1477179A1 Anion exchange resin adsorbed fraction, immunopotentiator and promoter for recovery from loaded stress originating in matsutake mushroom
11/17/2004	EP1477178A2 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
11/17/2004	EP1477175A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
11/17/2004	EP1477174A1 Radioactive arsenic-containing compounds and their uses in the treatment of tumors
11/17/2004	EP1476581A2 Recombinant bovine immunodeficiency virus based gene transfer system
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476545A2 Aggrecanase molecules
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476540A1 Methods for producing gama delta t cells
11/17/2004	EP1476471A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
11/17/2004	EP1476465A1 Method for producing interferon
11/17/2004	EP1476458A2 Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina)
11/17/2004	EP1476457A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SiNA)
11/17/2004	EP1476456A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/17/2004	EP1476454A1 Binding epitopes for helicobacter pylori and use thereof
11/17/2004	EP1476438A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
11/17/2004	EP1476434A2 Pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
11/17/2004	EP1476432A1 Therapeutic substituted indazole derivatives
11/17/2004	EP1476431A1 Tricyclic pyrazole derivatives for the treatment of inflammation
11/17/2004	EP1476426A2 Hydroxylated indirubin derivatives
11/17/2004	EP1476425A2 Heterocyclic arylsulfonamidobenzylic compounds
11/17/2004	EP1476423A2 Arylsulfonamidobenzylic compounds
11/17/2004	EP1476206A1 Compositions comprising undifferentiated fetal cells for the treatment of skin disordes
11/17/2004	EP1476200A2 Compositions and method for regulation of calcium-dependent signalling in brain
11/17/2004	EP1476199A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
11/17/2004	EP1476192A1 Methods and compositions for treating hyperproliferative conditions
11/17/2004	EP1476190A1 Amino-substituted hypocrellins for use as sonosensitizers
11/17/2004	EP1476185A2 Antibodies to cd40
11/17/2004	EP1476180A2 Interleukin-2 mutants with reduced toxicity
11/17/2004	EP1476175A2 Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
11/17/2004	EP1476166A1 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
11/17/2004	EP1476165A1 Substituted pyrimidinones and pyrimidinthiones
11/17/2004	EP1476159A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof
11/17/2004	EP1476158A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476157A1 Nicotinamide derivatives useful as pde4 inhibitors
11/17/2004	EP1476154A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
11/17/2004	EP1476149A2 Substituted hydrazones as inhibitors of cyclooxygenase-2
11/17/2004	EP1476143A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
11/17/2004	EP1476127A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity

1 ... 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 ... 2211